Tetra Radar · FDA Approvals · Decision date

DTX401: FDA decision date

Ultragenyx Pharmaceutical Inc (RARE) · 23 August 2026

The FDA granted the BLA Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) action date of August 23, 2026.

Source: 10-Q of 5 August 2026

The FDA approved it on 19 August 2026.

The FDA approved GENGLYCOS to reduce daily cornstarch intake as an adjunct to nutritional management in adult and pediatric patients 8 years of age and older with glycogen storage disease type Ia (GSDIa).

Ultragenyx Pharmaceutical Inc on Tetra Radar

A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.

Get the Dispatch free.